Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life

被引：49

作者：

Puente, V. ^{[1
]}

De Fabregues, O. ^{[2
]}

Oliveras, C. ^{[1
]}

Ribera, G. ^{[2
]}

Pont-Sunyer, C. ^{[1
]}

Vivanco, R. ^{[1
]}

Cucurella, G. ^{[1
]}

Giralt, E. ^{[1
]}

Delgado, T. ^{[2
]}

Garcia, C. ^{[2
]}

Seoane, A. ^{[3
]}

Campo, R. ^{[4
]}

机构：

[1] Univ Autonoma Barcelona, Dept Neurol, Inst Municipal Invest Med, Hosp Mar, E-08193 Barcelona, Spain

[2] Hosp Sabadell CS Parc Taulh, Dept Neurol, Sabadell, Spain

[3] Univ Autonoma Barcelona, Dept Gastroenterol, Inst Municipal Invest Med, Hosp Mar, E-08193 Barcelona, Spain

[4] Hosp Sabadell CS Parc Taulh, Dept Gastroenterol, Sabadell, Spain

来源：

PARKINSONISM & RELATED DISORDERS | 2010年 / 16卷 / 03期

关键词：

Parkinson's disease; Continuous intraduodenal levodopa; Infusion; Duodopa; Monotherapy; Fluctuations; Quality of life;

D O I：

10.1016/j.parkreldis.2009.07.015

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Symptom control, daily "on" time, and quality of life (QoL) of nine patients with Advanced Parkinson's Disease was assessed following 18-months treatment with Continuous Intraduodenal Levodopa Infusion (CIDLI). Patients had severe motor fluctuations and dyskinesias and had previously received treatment with oral levodopa and dopamine agonists There were significant improvements in patients' symptoms on the Unified Parkinson's Disease Rating Scale, and QoL (Parkinson's Disease QoL Questionnaire. Schwab & England Capacity for Daily Living Scale, p < 0 05) Mean (+/- SD) daily "on" time increased from 6 1 1 9 to 12.0 +/- 34 h (p < 0 05) Improved QoL in APD was associated with CIDLI-related improvements m symptom control and increase in daily "on" time (C) 2009 Published by Elsevier Ltd

引用

页码：218 / 221

页数：4

共 13 条

[1]

Agid Y, 1999, MOVEMENT DISORD, V14, P911, DOI 10.1002/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO

[2]

2-H

[3]

[Anonymous], 1982, Mov. Disorders

[4] Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome [J].

Antonini, Angelo ;

Isaias, Ioannis U. ;

Canesi, Margherita ;

Zibetti, Maurizio ;

Mancini, Francesca ;

Manfredi, Luigi ;

Dal Fante, Marco ;

Lopiano, Leonardo ;

Pezzoli, Gianni .

MOVEMENT DISORDERS, 2007, 22 (08) :1145-1149

[5] INTRADUODENAL INFUSION OF A WATER-BASED LEVODOPA DISPERSION FOR OPTIMIZATION OF THE THERAPEUTIC EFFECT IN SEVERE PARKINSONS-DISEASE [J].

BREDBERG, E ;

NILSSON, D ;

JOHANSSON, K ;

AQUILONIUS, SM ;

JOHNELS, B ;

NYSTROM, C ;

PAALZOW, L .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 45 (02) :117-122

[6] ERRATIC GASTRIC-EMPTYING OF LEVODOPA MAY CAUSE RANDOM FLUCTUATIONS OF PARKINSONIAN MOBILITY [J].

KURLAN, R ;

ROTHFIELD, KP ;

WOODWARD, WR ;

NUTT, JG ;

MILLER, C ;

LICHTER, D ;

SHOULSON, I .

NEUROLOGY, 1988, 38 (03) :419-421

[7] DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF DUODENAL INFUSION OF LEVODOPA CARBIDOPA IN PARKINSONS-DISEASE PATIENTS WITH ON-OFF FLUCTUATIONS [J].

KURTH, MC ;

TETRUD, JW ;

TANNER, CM ;

IRWIN, I ;

STEBBINS, GT ;

GOETZ, CG ;

LANGSTON, JW .

NEUROLOGY, 1993, 43 (09) :1698-1703

[8]

*NAT PARK FDN HOEH, UN PARK DIS RAT SCAL

[9] Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease [J].

Nyholm, D ;

Remahl, AIMN ;

Dizdar, N ;

Constantinescu, R ;

Holmberg, B ;

Jansson, R ;

Aquilonius, SM ;

Askmark, H .

NEUROLOGY, 2005, 64 (02) :216-223

[10] Optimizing levodopa phannacokinetics:: Intestinal infusion versus oral sustained-release tablets [J].

Nyholm, D ;

Askmark, H ;

Gomes-Trolin, C ;

Knutson, T ;

Lennernäs, H ;

Nyström, C ;

Aquilonius, SM .

CLINICAL NEUROPHARMACOLOGY, 2003, 26 (03) :156-163

← 1 2 →